Live Breaking News & Updates on Convergent Therapeutics|Page 1

Stay updated with breaking news from Convergent therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Prostate Cancer Treatment 225Ac-J591 Is Approved By The FDA

(CTN News) - The FDA Prostate Cancer has granted clearance to an investigational new drug (IND) application for 225Ac-J591..... ....

United States , Philip Kantoff , Convergent Therapeutics , American Association , Prostate Cancer Research Annual Meeting , Neil Bander ,

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Philip Kantoff , Drug Administration , Convergent Therapeutics Inc , Cornell University , Cancer Research , Convergent Therapeutics ,

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Philip Kantoff , Cornell University , Drug Administration , Cancer Research , Convergent Therapeutics Inc , Convergent Therapeutics ,

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

/PRNewswire/ Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for. ....

United Kingdom , Philip Kantoff , Cornell University , Drug Administration , Cancer Research , Convergent Therapeutics Inc , Convergent Therapeutics , Neil Bander ,

BioSpace Names Most Promising New Biopharma Companies to Watch in 2024

BioSpace Names Most Promising New Biopharma Companies to Watch in 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Josh Goodwin , Entact Bio , Nido Biosciences , Nextgen Class , Rapport Therapeutics , Apogee Therapeutics , Aera Therapeutics , Gen Bio , Orbital Therapeutics , Abdera Therapeutics , Bitterroot Bio , Convergent Therapeutics , Ascidian Therapeutics , Delve Bio , Alterome Therapeutics , Actio Biosciences , Initial Therapeutics , Rezo Therapeutics , Aether Bio , Belharra Therapeutics , Kate Therapeutics , Cajal Neuroscience , Matchpoint Therapeutics , Bonum Therapeutics , Juvena Therapeutics ,